Skip to main content

Table 1 Select ongoing and pending clinical trials that allow prior treatment with a PD-1 or PD-L1 inhibitor

From: Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series

Clinicaltrials.gov identifier

Experimental agents

Regimen targets

Phase

Tumor type

NCT02899078

Nivolumab + Ibrutinib

PD-1 + BTK

1b/2

RCC

NCT02923531

Nivolumab + X4P-001

PD-1 + CXCR4

1b/2a

RCC

NCT02963610*

Pembrolizumab + Lenalidomide

PD-1 + immunomodulatory

1/2

NSCLC

NCT03083808

Pembrolizumab + Docetaxel/Pemetrexed/Gemcitabine

PD-1 + Chemotherapy

2

NSCLC

NCT03041181

Nivolumab + Docetaxel

PD-1 + Chemotherapy

2

NSCLC

NCT02437136

Pembrolizumab + Entinostat

PD-1 + HDAC

1b/2

NSCLC and melanoma

NCT02959437

Pembrolizumab + Azacitidine + Epacadostat

PD-1 + Chemotherapy + IDO-1

1/2

NSCLC**

NCT03084640

Pembrolizumab + CMP-001

PD-1 + TLR9

1b/2

melanoma

NCT03014648

Atezolizumab

PD-L1

2

NSCLC

  1. PD-1 programmed cell death protein 1, BTK: Bruton’s tyrosine kinase, RCC: renal cell carcinoma, CXCR4: C-X-C chemokine receptor type 4, NSCLC: non-small cell lung cancer, HDAC: histone deacetylases, IDO-1: Indoleamine 2,3-Dioxygenase 1, TLR9: Toll-like receptor 9, PD-L1 programmed death-ligand 1
  2. *Prior treatment with anti-PD-1/PD-L1 is only allowed for the Phase 2 portion of this trial (which is only for NSCLC patients)
  3. **Only the NSCLC cohort allows prior treatment with PD-1/PD-L1
  4. Please note that this table was constructed using the following search terms on clinicaltrials.gov on 5/12/2017: “Nivolumab AND previously treated”, “Pembrolizumab AND previously treated”, and “Atezolizumab AND previously treated”. After generating a list of trials, the eligibility criteria for each trial was manually screened for inclusion in this table